Go Pro
→ Ticker Revealed: Pre-IPO Access to 'Next Elon Musk' Company (From Banyan Hill Publishing) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
$0.60
$0.60
$0.48
▼
$25.44
$1.23M1.4122,322 shsN/A
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
$0.00
-98.8%		$0.03
$0.00
▼
$0.11
$16K-0.5329,964 shs290 shs
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
$2.16
-1.4%		$3.19
$2.16
▼
$13.40
$1.42M1.121.07 million shs37,118 shs
Inotiv, Inc. stock logo
NOTV
Inotiv
$0.01
-26.0%		$0.02
$0.08
▼
$2.95
$387K3.777.42 million shs243,786 shs
The 7 Hottest IPO Stories of 2026 Cover
The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
-98.83%-98.00%-99.20%-99.21%-99.63%
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
-1.37%-8.09%-34.74%-23.94%-83.56%
Inotiv, Inc. stock logo
NOTV
Inotiv
0.00%0.00%0.00%-77.80%-99.20%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
$0.60
$0.60
$0.48
▼
$25.44
$1.23M1.4122,322 shsN/A
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
$0.00
-98.8%		$0.03
$0.00
▼
$0.11
$16K-0.5329,964 shs290 shs
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
$2.16
-1.4%		$3.19
$2.16
▼
$13.40
$1.42M1.121.07 million shs37,118 shs
Inotiv, Inc. stock logo
NOTV
Inotiv
$0.01
-26.0%		$0.02
$0.08
▼
$2.95
$387K3.777.42 million shs243,786 shs
The 7 Hottest IPO Stories of 2026 Cover
The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
-98.83%-98.00%-99.20%-99.21%-99.63%
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
-1.37%-8.09%-34.74%-23.94%-83.56%
Inotiv, Inc. stock logo
NOTV
Inotiv
0.00%0.00%0.00%-77.80%-99.20%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
0.00
N/AN/AN/A
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
0.00
N/AN/AN/A
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
2.67
Moderate Buy$44.001,937.04% Upside
Inotiv, Inc. stock logo
NOTV
Inotiv
2.00
Hold$1.5013,413.51% Upside

Current Analyst Ratings Breakdown

Latest NOTV, CANF, BPTH, and ASLN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/2/2026
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$5.00 ➝ $8.00
(Data available from 9/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
$12M0.10N/AN/A($6.50) per share-0.09
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
N/AN/AN/AN/A$0.71 per shareN/A
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
$405K3.49N/AN/A$1.76 per share1.23
Inotiv, Inc. stock logo
NOTV
Inotiv
$507.36M0.00$0.01 per share0.82$3.96 per share0.00
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
-$44.22M-$21.92N/AN/AN/AN/A-8,454.87%-121.60%N/A
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
-$16.08M-$1.09N/AN/AN/AN/A-2,842.40%-337.48%11/12/2026 (Estimated)
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
-$7.63M-$22.80N/AN/AN/AN/AN/AN/AN/A
Inotiv, Inc. stock logo
NOTV
Inotiv
-$68.62M-$2.53N/AN/AN/A-17.14%-56.77%-8.91%N/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
N/AN/AN/AN/AN/A
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
N/AN/AN/AN/AN/A
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
N/AN/AN/AN/AN/A
Inotiv, Inc. stock logo
NOTV
Inotiv
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
N/A
1.05
1.05
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
N/A
0.86
0.86
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
N/A
2.93
N/A
Inotiv, Inc. stock logo
NOTV
Inotiv
N/A
0.27
0.21

Institutional Ownership

CompanyInstitutional Ownership
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
58.82%
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
5.74%
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
21.00%
Inotiv, Inc. stock logo
NOTV
Inotiv
18.17%

Insider Ownership

CompanyInsider Ownership
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
4.69%
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
0.72%
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
0.80%
Inotiv, Inc. stock logo
NOTV
Inotiv
7.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
302.04 million1.95 millionNo Data
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
1053.90 million5.73 millionNo Data
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
8655,000N/ANot Optionable
Inotiv, Inc. stock logo
NOTV
Inotiv
2,04634.89 million32.17 millionOptionable

Recent News About These Companies

Inotiv Successfully Completes Financial Restructuring Process
July 20, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260719371664/en/inotiv-successfully-completes-financial-restructuring-process/
Inotiv Announces Confirmation of Plan of Reorganization
July 14, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260714051019/en/inotiv-announces-confirmation-of-plan-of-reorganization/
Inotiv Secures DIP Financing Amid Bankruptcy and Delisting
June 8, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/inotiv-secures-dip-financing-amid-bankruptcy-and-delisting?utm_source=marketbeat.com&utm_medium=referral
Debt reduction deal sends microcap soaring
June 5, 2026  |  msn.comhttps://www.msn.com/en-ca/money/topstories/debt-reduction-deal-sends-microcap-soaring/ar-AA24WawK
Inotiv Reaches Agreement to Strengthen Capital Structure and Position Company for Future Growth
June 3, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260602272707/en/inotiv-reaches-agreement-to-strengthen-capital-structure-and-position-company-for-future-growth/
Inotiv Extends Grace Period on Convertible Note Interest
June 1, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/inotiv-extends-grace-period-on-convertible-note-interest?utm_source=marketbeat.com&utm_medium=referral
Inotiv Secures Short-Term Waiver on Credit Agreement Liquidity
May 5, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/inotiv-secures-short-term-waiver-on-credit-agreement-liquidity?utm_source=marketbeat.com&utm_medium=referral
How The Inotiv (NOTV) Investment Story Is Shifting As Expectations And Risks Are Recast
April 16, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/inotiv-notv-investment-story-shifting-230726027.html
Inotiv Secures Temporary Waiver on Credit Agreement Liquidity Covenant
March 10, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/inotiv-secures-temporary-waiver-on-credit-agreement-liquidity-covenant?utm_source=marketbeat.com&utm_medium=referral
How Inotiv (NOTV) Narrative Is Shifting As Analysts Reset Fair Value Expectations
March 4, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/news/inotiv-notv-narrative-shifting-analysts-070745866.html
Inotiv Inc (NOTV) Q1 2026 Earnings Call Highlights: Navigating Growth Amidst Challenges
February 17, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/news/inotiv-inc-notv-q1-2026-010117673.html
Inotiv, Inc.: Inotiv Provides Notice Regarding Cybersecurity Incident
February 14, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-02/67703146-inotiv-inc-inotiv-provides-notice-regarding-cybersecurity-incident-399.htm
Inotiv, Inc. Issues Public Notice Regarding Cybersecurity Incident from August 2025
February 13, 2026  |  quiverquant.comQ
Inotiv Provides Notice Regarding Cybersecurity Incident
February 13, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/02/13/3238338/0/en/inotiv-provides-notice-regarding-cybersecurity-incident.html
Inotiv, Inc. (NASDAQ: NOTV) Q1 2026 earnings call transcript
February 10, 2026  |  msn.comhttps://www.msn.com/en-us/money/companies/inotiv-inc-nasdaq-notv-q1-2026-earnings-call-transcript/ar-AA1W3DKg
Inotiv slides after Q1 revenue falls short and losses deepen
February 9, 2026  |  msn.comhttps://www.msn.com/en-us/money/other/inotiv-slides-after-q1-revenue-falls-short-and-losses-deepen/ar-AA1VZB3Z
Inotiv Earnings Call: DSA Momentum vs. Debt Risks
February 9, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/inotiv-earnings-call-dsa-momentum-vs-debt-risks?utm_source=marketbeat.com&utm_medium=referral
Inotiv, Inc. (NOTV) Q1 2026 Earnings Call Transcript
February 9, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4867714-inotiv-inc-notv-q1-2026-earnings-call-transcript
Inotiv, Inc. Reports Slight Revenue Increase and Higher Operating Loss for Q1 FY 2026
February 9, 2026  |  quiverquant.comQ
Inotiv Reports First Quarter Financial Results for Fiscal 2026 and Provides Business Update
February 9, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/02/09/3234389/0/en/inotiv-reports-first-quarter-financial-results-for-fiscal-2026-and-provides-business-update.html

New MarketBeat Followers Over Time

ASLAN Pharmaceuticals stock logo

ASLAN Pharmaceuticals NASDAQ:ASLN

$0.60 0.00 (0.00%)
As of 09/9/2026

ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises eblasakimab (ASLAN004), a monoclonal antibody that targets the IL-13 receptor a1 subunit which is under Phase 2 developed for the treatment of atopic dermatitis and other immunology indications; and farudodstat (ASLAN003), an orally active, potent inhibitor of human dihydroorotate dehydrogenase currently under Phase 2 clinical trials for the treatment of autoimmune diseases. It has research collaboration agreement with Zenyaku Kogyo Co., Ltd. for the development and commercialization of eblasakimab in atopic dermatitis and all other indications in Japan. The company was founded in 2010 and is headquartered in Singapore.

Bio-Path stock logo

Bio-Path NASDAQ:BPTH

$0.0003 -0.03 (-98.83%)
As of 09/10/2026 10:49 AM Eastern

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing BP1001-A that is in Phase I clinical trial for the treatment of solid tumors; Liposomal Bcl-2 (BP1002), which is in Phase I clinical trial for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; and Liposomal STAT3 (BP1003) for treating pancreatic cancer, non-small cell lung cancer, and AML. The company was founded in 2007 and is based in Bellaire, Texas.

Can-Fite BioPharma stock logo

Can-Fite BioPharma NYSE:CANF

$2.16 -0.03 (-1.37%)
Closing price 09/10/2026 04:00 PM Eastern
Extended Trading
$2.23 +0.07 (+3.24%)
As of 05:33 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.

Inotiv stock logo

Inotiv NASDAQ:NOTV

Inotiv, Inc. provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries. It operates through two segment: Discovery and Safety Assessment (DSA), and Research Models and Services (RMS). The DMS segment manufactured scientific instruments for life sciences research and the related software for use by pharmaceutical companies, universities, government research centers, and medical research institutions under the Company's BASi product line. The RMS segment engages in commercial production and sales of research models, diets, bedding, and bioproducts. The company offers research and discovery services, including computational toxicology, disease pharmacology, DMPK, safety pharmacology, discovery bioanalysis, exploratory, surgical models and medical device, and cell and molecular biology; non-clinical safety assessment includes general and genetic toxicology, regulated bioanalysis, carcinogenicity studies, and development and reproductive toxicology; pathology services, such as histology, digital, clinical, and medical device pathology; bioanalysis includes nonregulated discovery bioanalysis, biotherapeutics, and regulated preclinical and clinical bioanalysis; proteomics; and consulting services, as well as model and research services. The company operates in the United States, the Netherlands, and internationally. The company was formerly known as Bioanalytical Systems, Inc. and changed its name to Inotiv, Inc. in March 2021. Inotiv, Inc. was incorporated in 1974 and is headquartered in West Lafayette, Indiana.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas